Gedea Biotech reports results from placebo-controlled clinical trial of pHyph, an antibiotic-free treatment for bacterial vaginosis
· Symptom reduction was seen in 90% of patients and absence of symptoms was noted in 70% of patients · Clinical cure rate was 50,4% in the pHyph group, which is in line with many antibiotic treatments on the market · The rate of recurrence of BV was substantially lower at day 35 with pHyph, 13.9%, compared to the standard treatment, 47.5% and throughout the 4 monthsLund, Sweden, October 11, 2022. Gedea Biotech, an innovative women’s health company today reported top-line results from a clinical study, NEFERTITI, of its lead product, pHyph, a vaginal tablet for topical treatment of